579 followers
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. - PubMed - NCBI https://t.co/1qUtg9jL5v
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. - PubMed - NCBI https://t.co/1qUtg9jL5v
@NathaliaHolt @srqstockpicker Almost as good as simply retreating them with Adcetris. http://t.co/LYUvvUKzCR
$SGEN #ASH14 @AlpineBV_Miller @kokurasluck @dsobek Think 30% CR with Adcetris retreatment is for CD30+ pts only? http://t.co/IAUeAkZZNt
$SGEN #ASH14 @AlpineBV_Miller @kokurasluck @dsobek Think 30% CR with Adcetris retreatment is for CD30+ pts only? http://t.co/IAUeAkZZNt